Bayer Trasylol To Receive FDA Advisory Cmte. Review
This article was originally published in The Pink Sheet Daily
Labeling changes will likely be the subject of the Sept. 21 advisory committee meeting for aprotinin injection.
You may also be interested in...
FDA will convene an advisory committee meeting to discuss the risks and benefits of Bayer's transfusion-sparing agent following risk reports.
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.
Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.